Monoclonal antibody | |
---|---|
Type | Bi-specific T-cell engager |
Source | Human |
Target | DLL3 and CD3 |
Clinical data | |
Trade names | Imdelltra |
Other names | AMG757; AMG-757, tarlatamab-dlle |
License data |
|
Routes of administration | Intravenous |
Drug class | Antineoplastic |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
DrugBank |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C4664H7139N1259O1454S34 |
Molar mass | 105202.82 g·mol−1 |
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extended-scale small cell lung cancer.[1] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.[1]
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.[2]
It was approved for medical use in the United States in May 2024.[2][3]